Adalimumab-atto - Biologic Drug Details

Summary for adalimumab-atto

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	3

Pharmacology for adalimumab-atto

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for adalimumab-atto Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for adalimumab-atto Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for adalimumab-atto Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Adalimumab-atto

Last updated: February 27, 2026

What Drives Market Penetration of Adalimumab-atto?

Adalimumab-atto, marketed as Amjevita among other names, is a biosimilar developed by Amgen. It competes directly with the reference biologic Humira (adalimumab), which held a dominant position in autoimmune disorder therapies.

Key Market Drivers

• Patent expirations: The U.S. patent for Humira expired in January 2023, opening the pathway for biosimilar entry [1].

• Cost reduction: Biosimilars offer a 15-30% discount relative to originators, incentivizing healthcare payers and providers to switch, particularly in cost-sensitive markets [2].

• Regulatory approvals: Amgen secured FDA approval for adalimumab-atto in September 2023, establishing an initial foothold in the U.S. biosimilar market [3].

• Physician acceptance: Education campaigns and evidence supporting biosimilar equivalence influence prescriber adoption.

• Market penetration barriers: Patent litigation, supply chain logistics, and clinician hesitancy affect actual uptake rates.

Competitive Landscape

Drug Name	Developer	Launch Year	Market Share (2022)	Price Discount vs. Humira
Humira (originator)	AbbVie	2002	~80% (post-2022)	N/A
Amjevita (adalimumab-atto)	Amgen	2023	Emerging	20-30% lower
Other biosimilars	Multiple	2023–Present	<10% overall	Similar range

Financial Trajectory and Revenue Projections

Revenue Potential

• Market size: The global adalimumab market was valued at approximately USD 25 billion in 2022, with Humira contributing an estimated 80% [4].

• Biosimilar impact: Biosimilars could capture 50–70% of the adalimumab market in developed countries within 3-5 years [5].

• Pricing assumptions: Initial biosimilar pricing offers a 20–30% discount. Over time, discounts may widen as multiple competitors enter the market.

Revenue Estimates for Amgen

Year	Estimated Biosimilar Revenue (USD billions)	Assumptions
2023	0.2–0.3	Launch in U.S., early adopter phase
2024	0.5–0.8	Broader adoption, payor inclusion
2025	1.2–1.8	Expanded international presence, increased acceptance
2026+	Up to USD 3 billion	Market penetration stabilizes, competitive pricing

Cost Structure and Profitability

• Manufacturing costs: Biosimilar production costs are roughly 40–60% lower than originators once scale is achieved [6].

• Pricing dynamics: Entry of multiple biosimilars may lead to price erosion, compressing margins.

• Profit margins: Amgen's gross margins for biosimilars range around 60–70%, with net margins varying based on market share and approval timing.

Regulatory and Reimbursement Factors

• The U.S. Centers for Medicare and Medicaid Services (CMS) began including biosimilars in multiple formulary coverage policies, facilitating reimbursement.

• International approvals vary, with Europe approving adalimumab biosimilars since 2018, which influences global market share.

Challenges and Opportunities

Challenges

• Patent litigations delaying market entry in certain regions.

• Market hesitancy from prescribers despite evidence of biosimilarity.

• Supply chain logistics for large-scale biologic manufacturing.

Opportunities

• Increasing adoption in rheumatology, gastroenterology, and dermatology.

• Expansion into emerging markets with high prevalence of autoimmune diseases.

• Strategic partnerships for distribution and clinical education.

Key Takeaways

• The biosimilar adalimumab-atto is expected to significantly alter the adalimumab market landscape post-2023.

• Early revenue projections suggest rapid growth, potentially reaching USD 1 billion annually within three years.

• Costs associated with biosimilar manufacturing and market entry are decreasing, improving profitability prospects.

• Regulatory and payor acceptance will determine the pace and extent of market share capture.

• Competitive pressure will influence pricing strategies and profit margins over the next five years.

FAQs

1. How does adalimumab-atto compare clinically to the originator Humira?
Regulatory agencies like the FDA approve biosimilars when they demonstrate no clinically meaningful differences in safety, purity, and potency, supported by extensive analytical, preclinical, and clinical data.

2. What is the timeline for biosimilar market penetration in the U.S.?
Market penetration is projected to accelerate over 3–5 years post-approval, reaching significant market shares as payors favor lower-cost options and prescriber confidence grows.

3. How will pricing evolve for adalimumab biosimilars?
Initial discounts are around 20–30%, but increased competition is expected to drive further price reductions, possibly up to 40–50% below the originator.

4. Which regions present the best opportunities for adalimumab-atto?
The U.S. and Europe offer early opportunities; emerging markets in Asia and Latin America are attractive due to high disease prevalence and cost-sensitive healthcare systems.

5. What risks could hinder adalimumab-atto’s market success?
Patent disputes, clinician resistance, manufacturing delays, and aggressive pricing from competitors can slow market adoption.

---

References

[1] Food and Drug Administration. (2023). "Amgen’s Amjevita (adalimumab-atto) approved." FDA.gov.

[2] IQVIA Institute. (2022). "The Global Use of Biosimilars."

[3] FDA. (2023). "Biologics Price Competition and Innovation Act (BPCIA) approvals."

[4] Fortune Business Insights. (2022). "Adalimumab Market Size, Share & Industry Analysis."

[5] Deloitte Center for Health Solutions. (2021). "Biosimilar market forecast."

[6] Cell & Gene. (2021). "Manufacturing Cost Trends and Opportunities in Biosimilars."